Country: Canada
Language: English
Source: Health Canada
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE); BENZOYL PEROXIDE
TARO PHARMACEUTICALS INC
D10AF51
CLINDAMYCIN, COMBINATIONS
1%; 5%
GEL
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 1%; BENZOYL PEROXIDE 5%
TOPICAL
10G (CLINDA) & 2 OZ (BENZ. PEROX))
Prescription
ANTIBIOTICS
Active ingredient group (AIG) number: 0242561001; AHFS:
APPROVED
2017-05-31
PRODUCT MONOGRAPH PR TARO-BENZOYL PEROXIDE / CLINDAMYCIN KIT TOPICAL GEL benzoyl peroxide and clindamycin gel, 5% / 1%, w/w (as clindamycin phosphate) Acne Vulgaris Therapy ATC Code: D10AF Taro Pharmaceuticals Inc. 130 East Drive Brampton, ON L6T 1C1 Date of Revision: August 17, 2018 Submission Control No.: 216759 _Page 2 of 20_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION......................................................... 3 SUMMARY PRODUCT INFORMATION................................................................................ 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 5 DRUG INTERACTIONS ........................................................................................................... 6 DOSAGE AND ADMINISTRATION ....................................................................................... 7 OVERDOSAGE ......................................................................................................................... 8 ACTION AND CLINICAL PHARMACOLOGY ...................................................................... 8 STORAGE AND STABILITY ................................................................................................... 8 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................... 8 PART II: SCIENTIFIC INFORMATION ................................................................................. 9 PHARMACEUTICAL INFORMATION ................................................................................... 9 CLINICAL TRIALS ................................................. Read the complete document